FDA Authorizes Marketing of Medasense’s Nociception Monitoring Tech
The FDA granted marketing authorization to Medasense Biometrics’ PMD-200 patient monitor with NOL technology for monitoring nociception.
The FDA granted marketing authorization to Medasense Biometrics’ PMD-200 patient monitor with NOL technology for monitoring nociception.
Zynex—a medical device company—has submitted a 510(k) application to the FDA for its fluid monitoring system.
The FDA granted marketing authorization to Medasense Biometrics’ PMD-200 patient monitor with NOL technology for monitoring nociception.